225 related articles for article (PubMed ID: 16048921)
1. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Gumbo T; Louie A; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
[TBL] [Abstract][Full Text] [Related]
3. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
5. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
6. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
7. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.
Grimaldo ER; Tupasi TE; Rivera AB; Quelapio MI; Cardaño RC; Derilo JO; Belen VA
Int J Tuberc Lung Dis; 2001 Jun; 5(6):546-50. PubMed ID: 11409582
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolones: a new treatment for tuberculosis?
Gillespie SH; Kennedy N
Int J Tuberc Lung Dis; 1998 Apr; 2(4):265-71. PubMed ID: 9559396
[TBL] [Abstract][Full Text] [Related]
10. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
11. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.
de Steenwinkel JE; de Knegt GJ; ten Kate MT; van Belkum A; Verbrugh HA; Kremer K; van Soolingen D; Bakker-Woudenberg IA
J Antimicrob Chemother; 2010 Dec; 65(12):2582-9. PubMed ID: 20947621
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.
Wu B; Derendorf H
Pharmazie; 2010 Jun; 65(6):417-20. PubMed ID: 20614689
[TBL] [Abstract][Full Text] [Related]
14. Antituberculosis agents. IX. In vitro antimycobacterial activity of N-(2-phenyl-2-oxoethyl) and N-[2-(4-fluorophenyl)-2-oxoethyl]ciprofloxacin derivatives against some drug-resistant strains of Mycobacterium tuberculosis and Mycobacterium avium isolates.
Foroumadi A; Soltani F
Boll Chim Farm; 2003; 142(6):248-50. PubMed ID: 14606264
[TBL] [Abstract][Full Text] [Related]
15. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
16. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
[TBL] [Abstract][Full Text] [Related]
20. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis.
Ahmad Z; Sharma S; Khuller GK; Singh P; Faujdar J; Katoch VM
Int J Antimicrob Agents; 2006 Dec; 28(6):543-4. PubMed ID: 17101262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
